Guardant Health (GH)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Guardant Health (GH)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Insights
Critical company metrics and information
Share Price
$38.11Market Cap
$4.71 BillionTotal Outstanding Shares
123.56 Million SharesTotal Employees
1,779Dividend
No dividendIPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesHomepage
https://www.guardanthealth.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-294.83 Million |
Net Cash Flow From Operating Activities, Continuing | $-51.06 Million |
Net Cash Flow From Investing Activities, Continuing | $-294.83 Million |
Net Cash Flow | $-346.87 Million |
Exchange Gains/Losses | $1.90 Million |
Net Cash Flow From Financing Activities, Continuing | $-2.88 Million |
Net Cash Flow From Financing Activities | $-2.88 Million |
Net Cash Flow, Continuing | $-348.77 Million |
Net Cash Flow From Operating Activities | $-51.06 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $-107.72 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Benefits Costs and Expenses | $299.20 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-107.75 Million |
Revenues | $191.48 Million |
Basic Average Shares | $123.05 Million |
Diluted Average Shares | $123.05 Million |
Operating Income/Loss | $-117.33 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income Tax Expense/Benefit | $30000.00 |
Diluted Earnings Per Share | $0.88 |
Net Income/Loss | $-107.75 Million |
Operating Expenses | $308.80 Million |
Basic Earnings Per Share | $0.88 |
Other Operating Expenses | $221.50 Million |
Costs And Expenses | $308.80 Million |
Income/Loss From Continuing Operations After Tax | $-107.75 Million |
Net Income/Loss Attributable To Parent | $-107.75 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Research and Development | $87.31 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $197.34 Million |
Liabilities And Equity | $1.54 Billion |
Intangible Assets | $7.25 Million |
Noncurrent Liabilities | $1.40 Billion |
Current Assets | $1.23 Billion |
Liabilities | $1.60 Billion |
Equity Attributable To Parent | $-60.10 Million |
Equity | $-60.10 Million |
Other Non-current Assets | $179.59 Million |
Inventory | $72.30 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Assets | $1.54 Billion |
Noncurrent Assets | $312.01 Million |
Accounts Payable | $15.47 Million |
Other Current Assets | $1.15 Billion |
Other Current Liabilities | $181.87 Million |
Fixed Assets | $125.17 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.